BioSpace News Archive

The Insight Partners published latest research report on “Organ Preservation Solution Market Size Report, Share, Trends & Revenue Forecast to 2028 - COVID-19 Impact and Global Analysis

Endogenex, Inc., a clinical stage medical device company, is proud to announce the addition of Christopher Sorli, M.D., Ph.D., as Chief Medical Officer.

According to a recent study by Université Clermont Auvergne researchers, exposure to chemical additives and building blocks commonly used in everyday plastic products, even in low doses, can cause significant damage to the genetic material carried by sperm cells.

Kynos Therapeutics Ltd, a biotechnology company developing a portfolio of first in class kynurenine 3-monooxygenase (KMO) inhibitors

Fractyl Health today presented key findings from its preclinical Rejuva® program at the American Society of Gene & Cell Therapy (ASGCT) Congress.

Zymo Research, a leading provider in the biomedical industry, has teamed up with Burst Diagnostics, a pioneer in the rapid diagnostics industry, to launch a first-in-class diagnostic platform.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) applauds the United States Supreme Court’s unanimous opinion1 ending a nearly decade-long patent dispute related to the Regeneron-invented PCSK9 inhibitor, Praluent® (alirocumab).

An Octapharma-sponsored study published recently in The Journal of Clinical Immunology concludes that cutaquig® (Immune Globulin Subcutaneous [Human]-hipp, 16.5% solution) infusions at higher infusion rates, volume and therapy intervals met study endpoints for efficacy and safety, and were generally well tolerated with reduced infusion time, fewer infusion sites, and reduced frequency.

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. announced that England’s National Institute for Health and Care Excellence has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.

Revvity, Inc., announced a new license agreement with AstraZeneca for the technology underlying its Pin-point™ base editing system, a next-generation modular gene editing platform with a strong safety profile.